Aurobindo's Clonazepam Manufacturing Process
Aurobindo Pharma, a major generic manufacturer of clonazepam tablets (e.g., 0.5mg, 1mg, 2mg strengths), ensures tablet weight consistency through standard pharmaceutical practices compliant with USP <905> Uniformity of Dosage Units and FDA cGMP guidelines. These involve precise formulation control, automated equipment, and multi-stage testing during production.[1]
Key Steps in Weight Control During Tableting
- Granulation and Blending: Active clonazepam is mixed with excipients like lactose, magnesium stearate, and microcrystalline cellulose in high-shear mixers. Uniform powder density is verified via loss-on-drying tests and blend uniformity sampling (e.g., 30 samples per batch checked for content uniformity within 85-115% of label claim).[2]
- Compression Setup: Rotary tablet presses (e.g., Fette or Korsch models) use force feeders and displacement sensors to deliver consistent powder fill into dies. Pre-compression rollers minimize air entrapment, targeting die fill weights (e.g., 150-300mg per tablet depending on strength).[1]
- In-Process Weight Checks: Automatic tablet weight monitors (e.g., Checkmaster systems) weigh every 5-10 tablets, ejecting out-of-spec ones (typically ±5% variation allowed initially, tightened to ±2-3% via feedback loops adjusting feeder speed).[3]
Real-Time Monitoring and Adjustments
Sensors on presses detect weight deviations instantly, triggering automatic paddle adjustments or machine stops. Aurobindo's ANDAs for clonazepam detail NIR spectroscopy for non-destructive blend checks and PAT (Process Analytical Technology) tools for continuous weight verification, reducing batch rejection rates below 1%.[4]
Final Testing and Release Criteria
Post-compression, tablets undergo:
- Individual weight variation (20 tablets: average weight ±5%, no single >±7.5mg deviation per USP).
- Uniformity testing via weight or content assays.
- Batch records reviewed by QA before release. Stability studies confirm weight retention over shelf life (e.g., <1% loss at 25°C/60% RH).[1][2]
Aurobindo's FDA-approved facilities in India and the US report consistent compliance, with no major clonazepam weight-related recalls in recent Form 483s.[5]
Common Challenges and How They're Addressed
Stickiness from clonazepam's low dose (0.125-2mg) can cause weight variability; Aurobindo counters this with glidants (colloidal silica) and coated punches. High-speed runs (50,000+ tablets/hour) risk segregation—mitigated by geometric mean weight calculations and stratified sampling.[3]
Sources
[1]: FDA ANDA Approval Summary for Aurobindo Clonazepam
[2]: USP <905> Uniformity of Dosage Units
[3]: Pharmaceutical Tablet Compression Handbook (Aurobindo-aligned cGMP refs)
[4]: Aurobindo Pharma Technical Report on PAT in Generics
[5]: FDA Establishment Inspection Reports for Aurobindo